ATS 2024 Final Program

Click on the session title to view the speakers

118

MONDAY • MAY 20

9:34 Interpretation of Pulmonary Function Testing in People Who are Transgender or Non-Binary 9:53 Sex Hormones and Asthma 10:12 Potential Impact of Gender Affirming Therapy on People with Cystic Fibrosis 10:31 General Discussion 10:40 Patient Speaker

BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL CLINICAL TOPICS IN PULMONARY MEDICINE B3 SPECIAL CONSIDERATIONS FOR PATIENTS WHO ARE TRANSGENDER OR NonBINARY IN PULMONARY MEDICINE Assemblies on Clinical Problems; Behavioral and Health Services Research; Clinical Problems; Pediatrics 9:15 a.m. - 10:45 a.m. San Diego Convention Center Room 7A-B (Upper Level) Target Audience Pediatric and adult providers of pulmonary medicine, clinicians who provide care to transgender and non-binary patients, clinical and translational researchers. Objectives At the conclusion of this session, the participant will be able to: • gain awareness of current gender minority health inequities in complex lung diseases, improve cultural humility for gender minorities, and implications of gender-affirming care on pulmonary disease to improve quality of life for gender minorities • identify knowledge gaps in clinical and translational research and demonstrate the importance of representing gender identity in pulmonary research in order to improve health outcomes of transgender and non-binary individuals • understand the impact of sex hormones on lung physiology and complex lung diseases such as cystic fibrosis, and asthma, and the potential impact of gender-affirming therapy on people with complex lung disease Transgender and non-binary individuals experience pervasive healthcare disparities and disproportionate exposure to risk factors of pulmonary disease. Much of clinical research utilizes sex as a variable but does not consider the role of gender or gender-affirming therapies such as chest binding, surgical intervention, or hormone therapy. This symposium will highlight healthcare disparities in the transgender and Non-binary population, educate clinicians on the impact of sex and gender on pulmonary disease, and review the impact of sex hormones on pulmonary disease such as asthma and cystic fibrosis. 9:15 Health Inequities and Pulmonary Considerations for People Who Are Transgender or Non-Binary

CLINICAL CRITICAL CARE TRACK

B4 EXTRACORPOREAL MEMBRANE

OXYGENATION (ECMO) FOR SEVERE ACUTE RESPIRATORY DISTRESS SYNDROME IN A POST-PANDEMIC WORLD

Assembly on Critical Care 9:15 a.m. - 10:45 a.m.

Marriott Marquis San Diego Marina Grand Ballroom 2-4 (Lobby Level, North Tower)

Target Audience All practicing healthcare providers, all levels Objectives

At the conclusion of this session, the participant will be able to: • review the current state of evidence regarding the use of VV-ECMO for ARDS and best practices for management, so that attendees can apply these concepts in patient care and research in the future • describe ongoing research in VV-ECMO and ARDS to demonstrate ongoing areas of uncertainty and identify future applications within critical care • identify factors that contribute to inequity and disparities in the use of VV-ECMO for ARDS and be cognizant of strategies for mitigation to provide equitable care The use of veno-venous (VV) extracorporeal membrane oxygenation (ECMO) as therapy for severe acute respiratory distress syndrome (ARDS) has increased exponentially due to advances in technology, prior respiratory pandemics, and emerging high-quality evidence. The recently released 2023 ARDS Practice Guidelines strongly recommend in favor of ECMO for the treatment of severe ARDS. The COVID pandemic shed light on the clinical, logistical, and ethical challenges faced when offering VV-ECMO during a time of healthcare strain. Clinical

ATS 2024 Conference Program • San Diego, CA